1,3-Dimethyl-4,5-diphenyl-2-[(2-oxopropyl)thio]imidazolium trifluorosulfonic acid salt

10 mg 520 € available

Art. No. D004
Synonym "L-683.685"; 1,3-Dimethyl-2-(2-oxopropylthio)-4,5-diphenyl-1H-imidazol-3-ium trifluoromethanesulfonate
Molecular Formula C21H21F3N2O4S2 (free cation: C20H21N2OS+)
Molecular Weight 486.53 (free cation: 337.46)
Purity > 95% (NMR)
Appearance off white solid
Solubility Pre-dissolve e.g. 2.02 mg in 207.6 μl DMSO to obtain a 20 mM stock solution - dilute 20 μl of that stock solution with 980 μl buffer (e.g. 50 mM TRIS-HCl, pH 7.5) to obtain a 400 μM solution
Application Inhibitior for transglutaminase.
The molecule was developed to block coagulation factor XIIIa, however the compound inhibits tissue transglutaminase as well. Both enzymes are inhibited with an IC50 of about 0.35 μM.
Storage Store at -20°C
Reference(s) Lorand et al., Exp. Eye Res., 1998, 66:531-6
Barsigian et al., J. Biol. Chem., 1991, 266:22501-9
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification


  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering


  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy